Pharmacology, Toxicology and Pharmaceutical Science
Disease
100%
Proteinase
100%
Neutrophil Cytoplasmic Antibody
100%
Vasculitis
100%
Calgranulin
100%
Rituximab
83%
Myeloblastin
83%
Remission
50%
ANCA Associated Vasculitis
50%
Biological Marker
33%
Myeloperoxidase
33%
Cyclophosphamide
16%
Azathioprine
16%
Keyphrases
Disease Relapse
100%
Vasculitis
100%
Proteinase
100%
Fecal Calprotectin
100%
S100A8
100%
Rituximab
55%
Antineutrophil Cytoplasmic Antibody
44%
High Risk
22%
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
22%
Remission Induction
22%
MPO-ANCA
22%
Relapse Risk
22%
Cyclophosphamide
11%
Treatment Initiation
11%
Large Cohort
11%
Prolonged Treatment
11%
Complete Remission
11%
Serum Levels
11%
Intensive Care Medicine
11%
Predicting the Future
11%
ANCA-associated Vasculitis
11%
Subgroup Analysis
11%
Percentage Reduction
11%
Calprotectin
11%
Proteinase 3
11%
Medicine and Dentistry
Disease
100%
Vasculitis
100%
Proteinase
100%
Calgranulin
100%
Neutrophil Cytoplasmic Antibody
100%
Rituximab
83%
Myeloblastin
83%
ANCA Associated Vasculitis
50%
Biological Marker
33%
Myeloperoxidase
33%
Cyclophosphamide
16%
Spontaneous Remission
16%
Azathioprine
16%
Subgroup Analysis
16%
Immunology and Microbiology
Neutrophil Cytoplasmic Antibody
100%
Vasculitis
100%
Rituximab
83%
ANCA Associated Vasculitis
50%
Cyclophosphamide
16%
Blood Level
16%
Azathioprine
16%